Infection risk of peripheral intravenous catheters: meta-synthesis of 18 prospective studies with 14,606 catheters
Rattachement africain : au. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
BACKGROUND: To quantify the incidence of peripheral intravenous catheter (PIVC) infections and to describe the influence of clinical characteristics, including dwell time, on risk. METHODS: Meta-synthesis of 18 prospective studies (16 randomized controlled trials and two prospective cohort studies) reporting PIVC infections. In total, 14,606 PIVCs (50,096 device-days) were studied from insertion to removal in seven Australian government hospitals. PIVC care was provided by clinical staff with daily follow up by research nurses. We calculated incidences and rates of local infection (without bloodstream infection [BSI]) and PIVC-associated bloodstream infection (i.e., primary BSI) using the National Healthcare Safety Network criteria. The hazard function was assessed by fitting a parametric survival model. PIVC-associated BSI was further categorized as PIVC-related BSI and/or Staphylococcus aureus BSI. Case study methodology explored characteristics of PIVC-associated BSI, and life tables explored the hazard function of PIVC-associated BSI over dwell time. RESULTS: Of 14,606 PIVCs (dwell 0-42 days), there were five local infections (0.034%; 0.100/1,000 device-days) and six PIVC-associated BSI (0.041%; 0.120/1,000 device-days), of which four were PIVC-related and one was S. aureus BSI. PIVC-associated BSI involved Enterobacter cloacae (n = 3 including one co-infection with Citrobacter braakii), Proteus mirabilis (n = 1), Pseudomonas aeruginosa (n = 1) and S. aureus (n = 1; S. aureus BSI incidence 0.007% catheters or 0.020/1000 device-days). PIVC-associated BSI cases commonly featured: males > 60 years with difficult intravenous access, delayed removal of idle or symptomatic PIVCs, cancer diagnoses, invasive gastrointestinal drains/procedures, insertion site complications, and forearm placement. PIVC-associated BSI daily hazard was constant over time with zero to 0.03% on Days 1 to 5 (n = 11,491), 0.06% to 0.10% on Days 6 and 7 (n = 2,571), and zero on Days 8 to 42 (n = 544). CONCLUSIONS: Infection incidence is very low but remains a serious risk, mainly for complex patients. Gram-negative organisms may now be predominant in Australia. Infection surveillance should be risk-adjusted and prevention efforts to improve both insertion and post-insertion management targeted at high-risk groups. While overall intravenous therapy (exposure) should be minimised, daily risk per PIVC appears constant for at least 5 days.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Infection risk of peripheral intravenous catheters: meta-synthesis of 18 prospective studies with 14,606 catheters
- Date Crossref
- 27/10/2025
- Éditeur
- Springer Science and Business Media LLC
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Griffith University Schools of Nursing and Midwifery and Pharmacy and Medical Sciences pays non établi dans la noticeUniversité ou école supérieure
-
Queensland Health pays non établi dans la noticeOrganisme public
-
The University of Queensland Australasian Kidney Trials Network pays non établi dans la noticeUniversité ou école supérieure
-
Royal Brisbane and Women's Hospital pays non établi dans la noticeÉtablissement de santé
-
Metro North Hospital and Health Service pays non établi dans la noticeÉtablissement de santé
-
Kidney Health Australia pays non établi dans la noticeOrganisation à but non lucratif
-
Princess Alexandra Hospital pays non établi dans la noticeÉtablissement de santé
-
Children's Medical Research Institute pays non établi dans la noticeStructure de recherche
-
Children’s Health Queensland Hospital and Health Service pays non établi dans la noticeÉtablissement de santé
-
Queensland University of Technology pays non établi dans la noticeUniversité ou école supérieure
-
Metro South Health pays non établi dans la noticeÉtablissement de santé
-
Herston Infectious Diseases Institute Metro North Health pays non établi dans la noticeStructure de recherche
Schools of Nursing and Midwifery and Pharmacy and Medical Sciences — Griffith University, Queensland Health et Australasian Kidney Trials Network — The University of Queensland, avec 9 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.